Revvity (RVTY) Stock Forecast & Price Target

Compare

553 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RVTY Analyst Ratings

Moderate Buy

6 Buy

6 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Revvity

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RVTY Stock 12 Month Forecast

Average Price Target

$113.73

▲(9.53% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Revvity in the last 3 months. The average price target is $113.73 with a high forecast of $129.00 and a low forecast of $105.00. The average price target represents a 9.53% change from the last price of $103.83.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"87":"$87","130":"$130","97.75":"$97.8","108.5":"$108.5","119.25":"$119.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":129,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$129.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":113.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$113.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$105.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[87,97.75,108.5,119.25,130],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.09,108.77538461538462,110.46076923076923,112.14615384615385,113.83153846153846,115.51692307692308,117.2023076923077,118.8876923076923,120.57307692307693,122.25846153846155,123.94384615384615,125.62923076923077,127.31461538461538,{"y":129,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.09,107.60076923076923,108.11153846153846,108.6223076923077,109.13307692307693,109.64384615384616,110.15461538461538,110.66538461538462,111.17615384615385,111.68692307692308,112.19769230769231,112.70846153846155,113.21923076923078,{"y":113.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.09,106.92923076923077,106.76846153846154,106.6076923076923,106.44692307692308,106.28615384615385,106.12538461538462,105.96461538461539,105.80384615384615,105.64307692307692,105.4823076923077,105.32153846153847,105.16076923076923,{"y":105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":125.773,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.832,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.015,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.706,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.133,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.823,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.11,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.988,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.636,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.533,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.367,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.691,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$129.00

Average Price Target$113.73

Lowest Price Target$105.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Daniel Brennan

TD Cowen

$120→$124

Buy

19.43%

Upside

Reiterated

02/03/26

Revvity: Undervalued Mid-Growth Name with Clear Margin Expansion Path Drives Buy Rating

Brandon Couillard

Wells Fargo

$107→$110

Hold

5.94%

Upside

Reiterated

02/03/26

Wells Fargo Reaffirms Their Hold Rating on Revvity (RVTY)

Catherine Ramsey Schulte

Robert W. Baird

$123→$129

Buy

24.24%

Upside

Reiterated

02/03/26

Revvity price target raised to $129 from $123 at BairdRevvity price target raised to $129 from $123 at Baird

Vijay Kumar

Evercore ISI

$112→$118

Buy

13.65%

Upside

Reiterated

02/03/26

Revvity price target raised to $118 from $112 at Evercore ISIRevvity price target raised to $118 from $112 at Evercore ISI

Daniel Arias

Stifel Nicolaus

$110

Hold

5.94%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (NYSE: THC), Revvity (NYSE: RVTY) and Biogen (NASDAQ: BIIB)

Casey Woodring

J.P. Morgan

$105

Hold

1.13%

Upside

Reiterated

02/03/26

J.P. Morgan Remains a Hold on Revvity (RVTY)

Unknown Analyst

UBS

Not Ranked

UBS

$115→$120

Buy

15.57%

Upside

Reiterated

02/03/26

Revvity (RVTY) Receives a Buy from UBS

Tycho Peterson

Jefferies

$100→$105

Hold

1.13%

Upside

Reiterated

02/02/26

Revvity price target raised to $105 from $100 at JefferiesRevvity price target raised to $105 from $100 at Jefferies

Michael Ryskin

Bank of America Securities

$110

Hold

5.94%

Upside

Reiterated

02/02/26

Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY) and Aktis Oncology, Inc. (NASDAQ: AKTS)

Luke Sergott

Barclays

$115

Buy

10.76%

Upside

Reiterated

02/02/26

Revvity (RVTY) Gets a Buy from Barclays

Unknown Analyst

Citi

Not Ranked

Citi

$135→

Buy

―

Reiterated

01/05/26

Citi Sticks to Their Buy Rating for Revvity (RVTY)

Evie Koslosky

Goldman Sachs

$105

Hold

1.13%

Upside

Initiated

12/09/25

Revvity initiated with a Neutral at Goldman SachsRevvity initiated with a Neutral at Goldman Sachs

Andrew Cooper

Raymond James

$115

Buy

10.76%

Upside

Reiterated

10/28/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Revvity (NYSE: RVTY)

Subbu Nambi

Guggenheim

Hold

―

Reiterated

10/27/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: HCA Healthcare (NYSE: HCA), Revvity (NYSE: RVTY) and ANI Pharmaceuticals (NASDAQ: ANIP)

Paul Knight

KeyBanc

$125

Buy

20.39%

Upside

Reiterated

09/16/25

KeyBanc Reaffirms Their Buy Rating on Revvity (RVTY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Daniel Brennan

TD Cowen

$120→$124

Buy

19.43%

Upside

Reiterated

02/03/26

Revvity: Undervalued Mid-Growth Name with Clear Margin Expansion Path Drives Buy Rating

Brandon Couillard

Wells Fargo

$107→$110

Hold

5.94%

Upside

Reiterated

02/03/26

Wells Fargo Reaffirms Their Hold Rating on Revvity (RVTY)

Catherine Ramsey Schulte

Robert W. Baird

$123→$129

Buy

24.24%

Upside

Reiterated

02/03/26

Revvity price target raised to $129 from $123 at BairdRevvity price target raised to $129 from $123 at Baird

Vijay Kumar

Evercore ISI

$112→$118

Buy

13.65%

Upside

Reiterated

02/03/26

Revvity price target raised to $118 from $112 at Evercore ISIRevvity price target raised to $118 from $112 at Evercore ISI

Daniel Arias

Stifel Nicolaus

$110

Hold

5.94%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (NYSE: THC), Revvity (NYSE: RVTY) and Biogen (NASDAQ: BIIB)

Casey Woodring

J.P. Morgan

$105

Hold

1.13%

Upside

Reiterated

02/03/26

J.P. Morgan Remains a Hold on Revvity (RVTY)

Unknown Analyst

UBS

Not Ranked

UBS

$115→$120

Buy

15.57%

Upside

Reiterated

02/03/26

Revvity (RVTY) Receives a Buy from UBS

Tycho Peterson

Jefferies

$100→$105

Hold

1.13%

Upside

Reiterated

02/02/26

Revvity price target raised to $105 from $100 at JefferiesRevvity price target raised to $105 from $100 at Jefferies

Michael Ryskin

Bank of America Securities

$110

Hold

5.94%

Upside

Reiterated

02/02/26

Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY) and Aktis Oncology, Inc. (NASDAQ: AKTS)

Luke Sergott

Barclays

$115

Buy

10.76%

Upside

Reiterated

02/02/26

Revvity (RVTY) Gets a Buy from Barclays

Unknown Analyst

Citi

Not Ranked

Citi

$135→

Buy

―

Reiterated

01/05/26

Citi Sticks to Their Buy Rating for Revvity (RVTY)

Evie Koslosky

Goldman Sachs

$105

Hold

1.13%

Upside

Initiated

12/09/25

Revvity initiated with a Neutral at Goldman SachsRevvity initiated with a Neutral at Goldman Sachs

Andrew Cooper

Raymond James

$115

Buy

10.76%

Upside

Reiterated

10/28/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Revvity (NYSE: RVTY)

Subbu Nambi

Guggenheim

Hold

―

Reiterated

10/27/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: HCA Healthcare (NYSE: HCA), Revvity (NYSE: RVTY) and ANI Pharmaceuticals (NASDAQ: ANIP)

Paul Knight

KeyBanc

$125

Buy

20.39%

Upside

Reiterated

09/16/25

KeyBanc Reaffirms Their Buy Rating on Revvity (RVTY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revvity

3 Months

xxx

Success Rate

23/35 ratings generated profit

Average Return

+2.43%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.71% of your transactions generating a profit, with an average return of +2.43% per trade.

1 Year

Daniel BrennanTD Cowen

Success Rate

7/11 ratings generated profit

Average Return

+2.29%

reiterated a buy rating 4 days ago

Copying Daniel Brennan's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +2.29% per trade.

2 Years

xxx

Success Rate

7/11 ratings generated profit

Average Return

-0.05%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of -0.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RVTY Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RVTY has received 11 Buy Ratings, 25 Hold Ratings, and 0 Sell Ratings. RVTY average Analyst price target in the past 3 months is 113.73.

Each month's total comprises the sum of three months' worth of ratings.

RVTY Financial Forecast

RVTY Earnings Forecast

Next quarter’s earnings estimate for RVTY is $1.03 with a range of $1.00 to $1.10. The previous quarter’s EPS was $1.70. RVTY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year RVTY has Performed in-line its overall industry.

RVTY Sales Forecast

Next quarter’s sales forecast for RVTY is $704.45M with a range of $697.00M to $709.98M. The previous quarter’s sales results were $772.06M. RVTY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year RVTY has Performed in-line its overall industry.

RVTY Stock Forecast FAQ

What is RVTY’s average 12-month price target, according to analysts?

Based on analyst ratings, Revvity’s 12-month average price target is 113.73.

What is RVTY’s upside potential, based on the analysts’ average price target?

Revvity has 9.53% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RVTY a Buy, Sell or Hold?

Revvity has a consensus rating of Moderate Buy which is based on 6 buy ratings, 6 hold ratings and 0 sell ratings.

What is Revvity’s price target?

The average price target for Revvity is 113.73. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $129.00 ,the lowest forecast is $105.00. The average price target represents 9.53% Increase from the current price of $103.83.

What do analysts say about Revvity?

Revvity’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of RVTY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Revvity (RVTY) Stock Forecast & Price Target

RVTY Analyst Ratings

RVTY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Revvity

RVTY Analyst Recommendation Trends

RVTY Financial Forecast

RVTY Earnings Forecast

RVTY Sales Forecast

RVTY Stock Forecast FAQ

Detailed List of Analyst Forecasts